Beijing University of Technology

Purdue Research Foundation

Monash University

Jian Li

Philip E Thompson

Roger L Nation

Kade D Roberts

Tony Velkov

Qi Zhou

Maizbha Uddin Ahmed

Mohammad Abul Kalam Azad

Philip Thompson

Roger Nation

The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

Inhalation formulations of antimicrobial compounds

The present invention relates to antimicrobial polymyxin derivative compounds and their uses, and in particular to peptide polymyxin antibiotics which may be used in the treatment of bacterial infections such as Gram negative bacterial infections, particularly those caused by multidrug-resistant (MDR) Gram negative bacterial infections.

Antimicrobial polymyxin derivative compounds

The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.

Polymyxin derivatives as antimicrobial compounds

Growing community of inventors

Carnegie, Australia

Jian Li